Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 13/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | SCN2B | O60939 | 1/20 | 0.52 |
| ▸ | SCN1A | P35498 | 1/20 | 0.52 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251089 | 0.85 | PLA2G4A (0.56) | PLA2G4AHDAC6HDAC1HDAC8SCN2B | |
| SCHEMBL1991870 | 0.82 | HDAC6 (0.63) | HDAC6HDAC1HDAC8 | |
| SCHEMBL1993104 | 0.81 | HDAC6 (0.53) | PLA2G4AHDAC6HDAC1HDAC8 | |
| SCHEMBL3122786 | 0.78 | PLA2G4A (0.61) | PLA2G4A | |
| SCHEMBL3129268 | 0.77 | PLA2G4A (1.00) | PLA2G4A | |
| SCHEMBL3128075 | 0.75 | PLA2G4A (0.81) | PLA2G4AHDAC6HDAC1HDAC8 | |
| SCHEMBL3128059 | 0.75 | PLA2G4A (0.81) | PLA2G4AHDAC6HDAC1HDAC8 | |
| SCHEMBL1994556 | 0.74 | HASPIN (0.61) | HDAC6HDAC1HDAC8 | |
| SCHEMBL1992307 | 0.72 | HASPIN (0.56) | HDAC6HDAC1HDAC8 | |
| SCHEMBL1993367 | 0.72 | HASPIN (0.47) | HDAC6HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371281-B2 | Indole derivatives as inhibitors of histone deacetylase | PHARMACYCLICS LLC (US) | 2016-06-21 | — | — | US | claimed |
| US-20150299119-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS LLC | 2015-10-22 | — | — | US | claimed |
| US-20150038542-A1 | USES OF SELECTIVE INHIBITORS OF HDAC8 AND TREATMENT OF INFLAMMATORY CONDITIONS | PHARMACYCLICS LLC | 2015-02-05 | — | — | US | claimed |
| US-20130078215-A1 | USES OF SELECTIVE INHIBITORS OF HDAC8 FOR TREATMENT OF INFLAMMATORY CONDITIONS | PHARMACYCLICS, INC. (US) | 2013-03-28 | — | — | US | claimed |
| US-20110150825-A1 | USES OF SELECTIVE INHIBITORS OF HDAC8 FOR TREATMENT OF INFLAMMATORY CONDITIONS | PHARMACYCLICS, INC. (US) | 2011-06-23 | — | — | US | claimed |
| US-9371281-B2 | Indole derivatives as inhibitors of histone deacetylase | PHARMACYCLICS LLC (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150299119-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS LLC | 2015-10-22 | — | — | US | disclosed |
| US-20150038542-A1 | USES OF SELECTIVE INHIBITORS OF HDAC8 AND TREATMENT OF INFLAMMATORY CONDITIONS | PHARMACYCLICS LLC | 2015-02-05 | — | — | US | disclosed |
| US-8900565-B2 | Indole derivatives as inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130156727-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130078215-A1 | USES OF SELECTIVE INHIBITORS OF HDAC8 FOR TREATMENT OF INFLAMMATORY CONDITIONS | PHARMACYCLICS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8338416-B2 | Indole derivatives as inhibitors of histone deacetylase | PHARMACYLICS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110150825-A1 | USES OF SELECTIVE INHIBITORS OF HDAC8 FOR TREATMENT OF INFLAMMATORY CONDITIONS | PHARMACYCLICS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-7820711-B2 | Uses of selective inhibitors of HDAC8 for treatment of T-cell proliferative disorders | PHARMACYCLICS INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20080112889-A1 | Uses of Selective Inhibitors of HDAC8 for Treatment of T-Cell Proliferative Disorders | PHARMACYCLICS, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20070281934-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299119-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC8, HDAC1, HDAC2 | PLA2G4A 3028/4885HDAC6 10/4885HDAC1 2/4885 |
| US-20080112889-A1 | Uses of Selective Inhibitors of HDAC8 for Treatment of T-Cell Proliferative Disorders | HDAC8, HDAC5, HDAC7 | PLA2G4A 3513/4885HDAC6 12/4885HDAC1 4/4885 |
| US-20110150825-A1 | USES OF SELECTIVE INHIBITORS OF HDAC8 FOR TREATMENT OF INFLAMMATORY CONDITIONS | HDAC8, HDAC2, HDAC7 | PLA2G4A 1179/4885HDAC6 9/4885HDAC1 5/4885 |
| US-20070281934-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC8, HDAC1, HDAC2 | PLA2G4A 3028/4885HDAC6 10/4885HDAC1 2/4885 |
| US-20130078215-A1 | USES OF SELECTIVE INHIBITORS OF HDAC8 FOR TREATMENT OF INFLAMMATORY CONDITIONS | HDAC8, HDAC2, HDAC7 | PLA2G4A 1179/4885HDAC6 9/4885HDAC1 5/4885 |
| US-20150038542-A1 | USES OF SELECTIVE INHIBITORS OF HDAC8 AND TREATMENT OF INFLAMMATORY CONDITIONS | HDAC8, HDAC2, HDAC7 | PLA2G4A 1247/4885HDAC6 9/4885HDAC1 5/4885 |
| US-20130156727-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC8, HDAC1, HDAC2 | PLA2G4A 3028/4885HDAC6 10/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.